All In MedTech

Device Trial Radar · NCT05958095

Curio Digital Therapy for the Treatment of Post-partum Depression

Supporting Maternal Mental Health and Emotional Regulation (SuMMER): Assessment of the Clinical Effectiveness of a Mobile Application for Patients With Postpartum Depression

Last checked: Nov 19, 2026Latest source record: Jul 24, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingRandomized with 142 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

142

Actual

Start

Apr 1, 2023

Primary completion

May 24, 2023

Study completion Aug 15, 2023

Sponsor

Lead sponsor
Healthcare Innovation Technology LabNot on our public-company list
Sponsor type
Industry
Collaborators
Curio Digital Therapeutics, Inc.
First posted
Jul 24, 2023

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Randomized
Model
Parallel
Masking
Single (participant)
Primary purpose
Treatment
FDA-regulated device
Yes
Who can join
Female only, from 18 years, up to 50 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

Primary Objective: Evaluate the clinical effectiveness of the MamaLift Plus app compared to control (digital sham plus treatment as usual) for the management of PPD in the observed population for a period of 9 calendar weeks. It is hypothesized that women who use the MamaLift Plus APP will experience less severe symptoms of depression in post-partum period than comparable women who do not and receive their usual care from health providers.

Conditions

  • PostPartum Depression

Interventions

  • MamaLift PlusDevice

    MamaLift Plus is a digital therapeutic designed to augment usual care and support the treatment of mild-to-moderate postpartum depression (PPD). This mobile-based intervention is grounded on principles of Cognitive Behavioral Therapy (CBT) and Interpersonal Therapy (IPT) and includes key content areas for the treatment management of PPD. It also includes recent developments in acceptance and commitment-based therapies, specifically for the perinatal context.

  • Digital Sham AppDevice

    The digital sham app delivers content, tips, and suggestion for general wellbeing support.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. EPDS ScoreTime frame: 9 week period
  2. EPDS Score improvementTime frame: 9 week period

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Healthcare Innovation and Technology Lab

    New York, New York

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.